Published in Eur J Cancer on August 06, 2008
The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med (2012) 1.21
Molecular targeted therapies in head and neck cancer--an update of recent developments-. Head Neck Oncol (2010) 1.03
Expression of Y-box-binding protein YB-1 allows stratification into long- and short-term survivors of head and neck cancer patients. Br J Cancer (2011) 0.92
Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study. Transl Oncol (2010) 0.87
Bioengineering strategies for designing targeted cancer therapies. Adv Cancer Res (2013) 0.86
A quest for initiating cells of head and neck cancer and their treatment. Cancers (Basel) (2010) 0.77
SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model. Toxins (Basel) (2010) 0.75
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol (2008) 10.29
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol (2009) 5.45
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol (2009) 3.20
Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med (2013) 2.96
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol (2009) 2.88
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch (2010) 2.72
HER2 testing in gastric cancer: a practical approach. Mod Pathol (2012) 2.68
An international Ki67 reproducibility study. J Natl Cancer Inst (2013) 2.46
Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions. Clin Cancer Res (2013) 2.29
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol (2014) 2.17
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat (2011) 1.89
Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol (2003) 1.87
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res (2008) 1.86
Atypical patterns of circadian clock gene expression in human peripheral blood mononuclear cells. J Mol Med (Berl) (2005) 1.73
[Ovarian epithelial dysplasia: Description of a dysplasia scoring scheme]. Ann Pathol (2011) 1.44
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch (2012) 1.34
Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol (2008) 1.27
Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol (2005) 1.27
ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res (2011) 1.26
Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat Med (2011) 1.23
Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics (2004) 1.21
Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res (2006) 1.20
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal (2014) 1.20
Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol (2002) 1.19
Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol (2010) 1.11
aHIF but not HIF-1alpha transcript is a poor prognostic marker in human breast cancer. Breast Cancer Res (2003) 1.08
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res (2003) 1.06
Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS One (2009) 1.05
Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist (2007) 1.05
Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett (2005) 1.04
Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res (2007) 1.01
Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet (2010) 1.01
Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral Oncol (2005) 1.00
Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. Pharmacogenomics (2007) 1.00
Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol (2008) 0.98
Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol (2011) 0.97
Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol (2007) 0.97
Comparative multi-methodological measurement of ERBB2 status in breast cancer. J Pathol (2004) 0.97
Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist (2008) 0.97
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol (2008) 0.97
Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes. Anticancer Drugs (2004) 0.96
Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics (2007) 0.96
Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol Rep (2008) 0.96
Epigenetic mechanisms of breast cancer: an update of the current knowledge. Epigenomics (2014) 0.95
Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. Eur J Gastroenterol Hepatol (2012) 0.95
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer (2013) 0.95
Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.94
High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat (2005) 0.94
High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study. Eur J Cancer (2006) 0.93
Diagnostic performance of one-step nucleic acid amplification for intraoperative sentinel node metastasis detection in breast cancer patients. Int J Cancer (2011) 0.93
The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer (2012) 0.93
Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. Int J Cancer (2010) 0.93
Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Arch (2006) 0.93
KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J Clin Oncol (2008) 0.93
Influence of the VEGF-A 936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer. Pharmacogenomics (2009) 0.92
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer (2011) 0.92
Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue. Breast Cancer Res Treat (2013) 0.92
Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer. Cancer (2011) 0.91
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. Breast Cancer Res (2011) 0.91
A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit (2006) 0.91
HCV glycoprotein E2 is a novel BDCA-2 ligand and acts as an inhibitor of IFN production by plasmacytoid dendritic cells. Blood (2012) 0.91
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. Br J Clin Pharmacol (2012) 0.90
Natural antisense transcripts of HIF-1alpha are conserved in rodents. Gene (2004) 0.90
Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial. Breast Cancer Res Treat (2013) 0.90
Prognostic factors in early-stage leiomyosarcoma of the uterus. Int J Gynecol Cancer (2009) 0.89
Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy. Breast Cancer Res Treat (2002) 0.89
Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. Crit Rev Oncol Hematol (2008) 0.89
Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification. Breast Cancer Res (2007) 0.89
Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PLoS One (2011) 0.88
Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status. Oncology (2003) 0.88
Current status of HER2 testing. Oncology (2002) 0.88
Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment? Oncol Rep (2006) 0.88
Does 99mTc-sestamibi uptake discriminate breast tumors? Cancer Invest (2004) 0.88
A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN). Cancer J (2008) 0.88
Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy. Gastroenterology (2014) 0.88
Dual role of Sp3 transcription factor as an inducer of apoptosis and a marker of tumour aggressiveness. PLoS One (2009) 0.88
Impact of glycosylation on the effect of cytokines. A special focus on oncology. Eur Cytokine Netw (2002) 0.88